PMV Pharmaceuticals

Apitope International NV is a biotechnology company based in Diepenbeek, Belgium, with a presence in the United Kingdom. Founded in 2002, it specializes in the discovery and development of therapeutic vaccines and peptides aimed at treating allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, and uveitis. Apitope's innovative approach focuses on developing disease-modifying therapies that selectively address the underlying causes of these conditions. Notable products in its pipeline include ATX-MS-1467 for multiple sclerosis, as well as candidates for Factor VIII intolerance and Graves’ disease. The company's proprietary platform technology supports its ongoing development efforts, with its first product candidate already licensed to a major pharmaceutical firm. Through its work, Apitope aims to enhance the quality of life for patients suffering from these challenging diseases.

FF Pharmaceuticals BV is a biopharmaceutical company based in Utrecht, the Netherlands, specializing in the development of disease-modifying therapeutics for inflammatory and autoimmune diseases. The company focuses on an anti-CD40 monoclonal antibody therapy designed to treat chronic inflammatory conditions such as primary biliary cirrhosis and Crohn's disease. This therapy acts as a negative allosteric modulator of the CD40 pathway, functioning as a reversible switch for B cell activation and inhibiting immune responses. By targeting the CD40 pathway, FF Pharmaceuticals aims to address the underlying immune dysregulation associated with these diseases, offering potential new treatment options for patients.